These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33833634)

  • 1. Combination Anti-IgE and Anti-IL5 Therapy in a Pediatric Patient With Severe Persistent Asthma.
    Fox HM; Rotolo SM
    J Pediatr Pharmacol Ther; 2021; 26(3):306-310. PubMed ID: 33833634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of mepolizumab and omalizumab combination therapy in uncontrolled asthma.
    Sezgin ME; Çolak M; Çağlayan Ö; Yumrukuz Şenel M; Aktepe Sezgin EN; Çoban H; Sarıoğlu N; Gemicioğlu B; Erel F
    J Asthma; 2024 Feb; 61(2):173-175. PubMed ID: 37530447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case study: A Combination of Mepolizumab and Omaluzimab injections for severe asthma.
    Dedaj R; Unsel L
    J Asthma; 2019 May; 56(5):473-474. PubMed ID: 29733738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of combination biologic therapy in uncontrolled severe asthma: a case study.
    Baccelli A; Koćwin M; Parazzini EM; Rinaldo RF; Centanni S
    J Asthma; 2023 May; 60(5):1050-1053. PubMed ID: 35913268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [SWITCHING BIOLOGICS LED TO GOOD CONTROL IN SEVERE CHILDHOOD ASTHMA: A CASE REPORT].
    Imai A; Takizawa T; Sato K; Inoue T; Nishida Y; Yagi H; Arakawa H
    Arerugi; 2019; 68(7):869-873. PubMed ID: 31406083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
    Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
    Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
    Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
    J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
    Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
    Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis: A Systematic Review and Meta-analysis.
    Rivero A; Liang J
    Ann Otol Rhinol Laryngol; 2017 Nov; 126(11):739-747. PubMed ID: 28918644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment.
    Davison J; Doe S
    Respir Med Case Rep; 2021; 34():101557. PubMed ID: 34877251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Monoclonal Antibody Therapy for a Severe Asthma Patient.
    Domingo C; Pomares X; Morón A; Sogo A
    Front Pharmacol; 2020; 11():587621. PubMed ID: 33101041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic "Overlap" severe asthma: Biological agent preference in atopic-eosinophilic severe asthma.
    Tepetam FM; Akyildiz AB; Özden Ş; Örcen C; Yakut T; Atik Ö
    Medicine (Baltimore); 2023 May; 102(18):e33660. PubMed ID: 37144999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma.
    AlShareef S; McDonald CF; Lee J
    J Asthma Allergy; 2022; 15():209-217. PubMed ID: 35210787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
    Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
    Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does NSAID exacerbated respiratory disease (N-ERD) accompanying severe asthma affect biological treatment response? Efficacy of omalizumab and mepolizumab in N-ERD.
    Tepetam FM; Özden Ş; Kılıç FK; Örçen C; Yakut T
    World Allergy Organ J; 2023 Sep; 16(9):100817. PubMed ID: 37771938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients.
    Valverde-Monge M; Sánchez-Carrasco P; Betancor D; Barroso B; Rodrigo-Muñoz JM; Mahillo-Fernández I; Arismendi E; Bobolea I; Cárdaba B; Cruz MJ; Del Pozo V; Domínguez-Ortega J; González-Barcala FJ; Olaguibel JM; Luna-Porta JA; Martínez-Rivera C; Mullol J; Muñoz X; Peleteiro-Pedraza L; Picado Valles C; Plaza V; Quirce S; Rial MJ; Soto-Retes L; Valero A; Sastre J
    Arch Bronconeumol; 2024 Jan; 60(1):23-32. PubMed ID: 38042707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.
    Fong WCG; Azim A; Knight D; Mistry H; Freeman A; Felongco M; Kyyaly A; Harvey M; Dennison P; Zhang H; Howarth P; Arshad SH; Kurukulaaratchy RJ
    Clin Exp Allergy; 2021 Aug; 51(8):1019-1032. PubMed ID: 33866615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein-protein interaction analyses.
    Akenroye A; Nopsopon T; Cho L; Moll M; Weiss ST
    Respir Res; 2023 Dec; 24(1):305. PubMed ID: 38057814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.